Who is eligible for PBS-subsidised nirmatrelvir and ritonavir, and molnupiravir?

Eligible adults with COVID-19, confirmed by a positive polymerase chain reaction (PCR) test or a rapid antigen test (RAT), may be eligible for PBS subsidised COVID-19 antiviral treatments, through a prescription from their doctor or authorised nurse practitioner.^1,2

Please see Table 1 for PBS eligibility criteria for the nirmatrelvir and ritonavir combination and molnupiravir and Table 2 for the complete list of risk factors.

Complete information on the PBS listings for nirmatrelvir and ritonavir (Paxlovid®) and molnupiravir (Lagevrio®), including eligibility criteria, is available on the PBS website at www.pbs.gov.au by using the search term “Paxlovid” or “Lagevrio” respectively.

^{Paxlovid® (nirmatrelvir and ritonavir) Pharmaceutical Benefits Scheme. Canberra: Australian Government Department of Health and Aged Care; 2024 Available from:}^{https://www.pbs.gov.au/medicine/item/12996B 13147Y}^{(accessed 6 June 2024).}
^{Lagevrio® (molnupiravir) Pharmaceutical Benefits Scheme. Canberra: Australian Government Department of Health and Aged Care; 2024. Available from:}^{https://www.pbs.gov.au/medicine/item/12910L-13144T}^{(accessed 6 June 2024).}